Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Haydon

Showing results (61-70 of 68) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 68 results.
British Journal of Cancer|April 16, 2009
O(6)-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatribA J Watson, M R Middleton, G McGown, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 28, 2015
A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanomaE M Hersh, M Del Vecchio, M P Brown, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 29, 2019
Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancerB Lee, L Lipton, J Cohen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 7, 2019
Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNAL Tan, S Sandhu, R J Lee, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 11, 2020
Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy<sup>☆</sup>C N Owen, A N Shoushtari, D Chauhan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 6, 2023
Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemiaS H Cass, J W D Tobin, Y D Seo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 2, 2021
Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanomaC N Owen, X Bai, T Quah, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 18, 2022
Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort studyF Dimitriou, K Namikawa, I L M Reijers, et al.
Pageof 7

Showing results (61-70 of 68) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 68 results.
British Journal of Cancer|April 16, 2009
O(6)-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatribA J Watson, M R Middleton, G McGown, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 28, 2015
A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanomaE M Hersh, M Del Vecchio, M P Brown, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 29, 2019
Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancerB Lee, L Lipton, J Cohen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 7, 2019
Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNAL Tan, S Sandhu, R J Lee, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 11, 2020
Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy<sup>☆</sup>C N Owen, A N Shoushtari, D Chauhan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 6, 2023
Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemiaS H Cass, J W D Tobin, Y D Seo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 2, 2021
Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanomaC N Owen, X Bai, T Quah, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 18, 2022
Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort studyF Dimitriou, K Namikawa, I L M Reijers, et al.
Pageof 7